Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
posted on
Jun 22, 2020 09:05AM
Bear, your answer lies in the ERA-EDTA presentation. Slide 17.
CKD patients had a longer mean duration of diabetes (11.3 vs. 8.2 years, P<0.001) and were less likely to be treated with metformin (69% vs. 84%, P<0.001) and SGLT2 inhibitors (6% vs. 13%, P=0.001)
I think its a good news, but we should ask the question about DPP4i's too.